Annals of Hematology

, Volume 83, Issue 7, pp 414–419 | Cite as

Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study

  • M. JerkemanEmail author
  • H. Anderson
  • M. Dictor
  • S. Kvaløy
  • M. Åkerman
  • E. Cavallin-Ståhl
Original Article


The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53, P-glycoprotein, and Ki-67. In a multivariate analysis, stratified for IPI, high BCL2 expression (>10%) low (<60%) expression of Ki-67, and high TP53 protein expression (>75%) were shown to provide additional prognostic information with regard to overall or failure-free survival. We found no association between expression of P-glycoprotein and outcome. Assessment of BCL2 positivity might be introduced as part of the routine investigation in patients with DLBCL, but further studies are necessary to confirm the clinical relevance of Ki-67 and TP53 expression.


BCL2 Diffuse large B-cell lymphoma P-glycoprotein Proliferation TP53 



This study was supported by grants from the Swedish Cancer Society, the foundations of the University Hospital of Lund, the Gunnar, Arvid, and Elisabeth Nilsson Foundation, and the Mrs Berta Kamprad Foundation. We also thank Carina Strand, Research Laboratory, Department of Oncology, Lund, and Christina Andersson, Immunohistochemistry Laboratory, Department of Pathology, Lund, for expert technical assistance.


  1. 1.
    Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16:2780–2795PubMedGoogle Scholar
  2. 2.
    Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci F, Sottili S, Campanacci M, et al. (1995) Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380–1385CrossRefPubMedGoogle Scholar
  3. 3.
    Finnegan MC, Royds J, Goepel JR, Lorigan P, Hancock BW, Goyns MH (1995) MDR-1 expression in non-Hodgkin’s lymphomas is unrelated to treatment intensity or response to therapy. Leuk Lymphoma 18:297–302PubMedGoogle Scholar
  4. 4.
    Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O’Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 90:244–251PubMedGoogle Scholar
  5. 5.
    Hermine O, Haioun C, Lepage E, d’Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyes F, Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 87:265–272Google Scholar
  6. 6.
    Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano P, Anderson L, Vaughan Hudson G, Mason D, Selby P, Linch DC (1996) Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood 88:1046–1051PubMedGoogle Scholar
  7. 7.
    Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534PubMedGoogle Scholar
  8. 8.
    Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaløy S, Sundström C, Åkerman M (1999) CHOP versus MACOP-B in aggressive lymphoma—a Nordic Lymphoma Group randomised trial. Ann Oncol 10:1079–1086Google Scholar
  9. 9.
    Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD (1997) Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin’s lymphoma. Blood 90:4078–4091PubMedGoogle Scholar
  10. 10.
    Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JH, de Jong D, Kluin PM (1996) Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 14:2131–2138PubMedGoogle Scholar
  11. 11.
    Lagorce-Pages C, le Tourneau A, Delmer A (1999) Proliferative activity in aggressive non-Hodgkin’s lymphomas: an immunohistochemical study with MIB-1 antibody of 991 cases from the GELA-LNH87 trial (abstract). Ann Oncol 10:87Google Scholar
  12. 12.
    Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, et al. (1994) Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin’s lymphomas: a prospective Southwest Oncology Group trial. Blood 83:1460–1466PubMedGoogle Scholar
  13. 13.
    Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K, Wick MR, Tsuruo T, Bloomfield CD (1992) Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 52:3768–3775PubMedGoogle Scholar
  14. 14.
    No authors listed (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994PubMedGoogle Scholar
  15. 15.
    Oka T, Sarker AB, Teramoto N, Yoshino T, Akagi T (1998) p53 protein expression in non-Hodgkin’s lymphomas is infrequently related to p53 gene mutations. Pathol Int 48:15–21PubMedGoogle Scholar
  16. 16.
    Osada M, Ishioka C, Ichinohasama R, Kadowaki I, Murakawa Y, Watanabe M, Kanamaru R, Ikawa S (1999) Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin’s lymphoma. Anticancer Drug Des 14:107–114PubMedGoogle Scholar
  17. 17.
    Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F, Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, et al. (1991) Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 19:131–140PubMedGoogle Scholar
  18. 18.
    Piris MA, Pezzella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Pezella F, et al. (1994) p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69:337–341PubMedGoogle Scholar
  19. 19.
    Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, Lopez L, Martinez-Montero JC, Orradre JL, Saez AI, Garcia JF, Piris MA (1998) Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 16:1931–1939PubMedGoogle Scholar
  20. 20.
    Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, et al. (1995) Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13:1995–2004PubMedGoogle Scholar
  21. 21.
    Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M (1997) Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood 89:601–609PubMedGoogle Scholar
  22. 22.
    Winter J N, Andersen J, Variakojis D, Gordon LI, Fisher RI, Oken MM, Neiman RS, Jiang S, Bauer KD (1996) Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin’s lymphomas. Blood 88:3919–3925PubMedGoogle Scholar
  23. 23.
    Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, Tobler A, Fey MF, Thatcher N, Yarbrough WG, Betticher DC (1998) Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 17:2779–2785CrossRefPubMedGoogle Scholar
  24. 24.
    Yuen AR, Sikic BI (1994) Multidrug resistance in lymphomas. J Clin Oncol 12:2453–2459PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • M. Jerkeman
    • 1
    Email author
  • H. Anderson
    • 2
  • M. Dictor
    • 3
  • S. Kvaløy
    • 4
  • M. Åkerman
    • 3
  • E. Cavallin-Ståhl
    • 1
  1. 1.Department of Oncology, Jubileum InstituteLund University HospitalLundSweden
  2. 2.Department of Cancer Epidemiology, Jubileum InstituteLund University HospitalLundSweden
  3. 3.Department of Pathology, Jubileum InstituteLund University HospitalLundSweden
  4. 4.Department of OncologyNorwegian Radium Hospital, MontebelloOsloNorway

Personalised recommendations